logo
Twitter
Discord
Email
logo
logo
Immunovant, Inc.NASDAQ - IMVT
Reports
Search reports
Name
Reporting Date
Filing Date
2024-12-31 10-Q2024-12-312025-02-06
2024-09-30 10-Q2024-09-302024-11-07
2024-06-30 10-Q2024-06-302024-08-06
2024-03-31 10-K2024-03-312024-05-29
2023-12-31 10-Q2023-12-312024-02-12
2023-09-30 10-Q2023-09-302023-11-09
2023-06-30 10-Q2023-06-302023-08-10
2023-03-31 10-K2023-03-312023-05-22
2022-12-31 10-Q2022-12-312023-02-03
2022-09-30 10-Q2022-09-302022-11-04
2022-06-30 10-Q2022-06-302022-08-05
2022-03-31 10-K2022-03-312022-06-08
2021-12-31 10-Q2021-12-312022-02-04
2021-09-30 10-Q2021-09-302021-11-05
2021-06-30 10-Q2021-06-302021-08-09
2021-03-31 10-K2021-03-312021-06-01
2020-12-31 10-Q2020-12-312021-02-16
2020-09-30 10-Q2020-09-302020-11-12
2020-06-30 10-Q2020-06-302020-08-12
2020-03-31 10-K2020-03-312020-06-29
1
2
20 / page
About
Name
Immunovant, Inc.
Overview
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Show More
CEO
Dr. Frank M. Torti M.B.A., M.D.
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2019-06-21
Address
320 West 37th Street, 6th Floor, New York, NY, 10018, United States
Tel
917-580-3099
Website
https://immunovant.com